Literature DB >> 30191051

The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?

Isabel Fabregat1,1, Gianluigi Giannelli2,2.   

Abstract

Entities:  

Keywords:  HCC; TGF-beta; targeted therapy

Year:  2017        PMID： 30191051      PMCID： PMC6095167          DOI： 10.2217/hep-2017-0012

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  18 in total

1.  Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.

Authors:  Andrea Malfettone; Jitka Soukupova; Esther Bertran; Eva Crosas-Molist; Raquel Lastra; Joan Fernando; Petra Koudelkova; Bhavna Rani; Ángels Fabra; Teresa Serrano; Emilio Ramos; Wolfgang Mikulits; Gianluigi Giannelli; Isabel Fabregat
Journal:  Cancer Lett       Date:  2017-02-02       Impact factor: 8.679

2.  PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression.

Authors:  A N M Fischer; E Fuchs; M Mikula; H Huber; H Beug; W Mikulits
Journal:  Oncogene       Date:  2006-11-20       Impact factor: 9.867

3.  Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.

Authors:  Shelli M Morris; Ji Yeon Baek; Amanda Koszarek; Samornmas Kanngurn; Sue E Knoblaugh; William M Grady
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 4.  Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment.

Authors:  Gianluigi Giannelli; Bhavna Rani; Francesco Dituri; Yuan Cao; Giuseppe Palasciano
Journal:  Gut       Date:  2014-07-21       Impact factor: 23.059

5.  Overactivation of the TGF-β pathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells.

Authors:  Esther Bertran; Eva Crosas-Molist; Patricia Sancho; Laia Caja; Judit Lopez-Luque; Estanislao Navarro; Gustavo Egea; Raquel Lastra; Teresa Serrano; Emilio Ramos; Isabel Fabregat
Journal:  Hepatology       Date:  2013-10-11       Impact factor: 17.425

6.  Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.

Authors:  Emilia Fransvea; Umberto Angelotti; Salvatore Antonaci; Gianluigi Giannelli
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

7.  Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.

Authors:  Armin Maier; Anne-Lise Peille; Vincent Vuaroqueaux; Michael Lahn
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

Review 8.  Role of NADPH oxidases in the redox biology of liver fibrosis.

Authors:  Eva Crosas-Molist; Isabel Fabregat
Journal:  Redox Biol       Date:  2015-07-14       Impact factor: 11.799

9.  NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.

Authors:  Yuan Cao; Rahul Agarwal; Francesco Dituri; Luigi Lupo; Paolo Trerotoli; Serena Mancarella; Peter Winter; Gianluigi Giannelli
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

10.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Authors:  Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  Cancer Res       Date:  2009-09-01       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.